Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Chief Business Officer | February 15, 2022 | February 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date February 15, 2022 · Filed February 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2032-02-14 | Direct | 550,000 |
Reported balance
After 2022-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-15 · Grant · Acquired 550,000 · Balance 550,000 F1: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2022 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2022 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 15, 2022 21:09 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-22-010056 · doc4.xml · derivative · entry 1 Shippy Richard · CIK 0001864622 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2022 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| June 15, 2021 Filed Jun 15, 2021 21:21 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001209191-21-040798 · doc4.xml · derivative · entry 1 Shippy Richard · CIK 0001864622 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on June 14, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from June 14, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2018 Equity Incentive Plan) through each such applicable vesting date and the terms of the Company's 2018 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.